📣 VC round data is live. Check it out!
- Public Comps
- Orchestra BioMed
Orchestra BioMed Valuation Multiples
Discover revenue and EBITDA valuation multiples for Orchestra BioMed and similar public comparables like Asterasys, Stratec, OraSure, Affluent Medical and more.
Orchestra BioMed Overview
About Orchestra BioMed
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Founded
2018
HQ

Employees
70
Website
Financials (LTM)
EV
$165M
Valuation Multiples
Start free trialOrchestra BioMed Financials
Orchestra BioMed reported last 12-month revenue of $20M and negative EBITDA of ($69M).
In the same LTM period, Orchestra BioMed generated $20M in gross profit, ($69M) in EBITDA losses, and had net loss of ($70M).
Revenue (LTM)
Orchestra BioMed P&L
In the most recent fiscal year, Orchestra BioMed reported revenue of $33M and EBITDA of ($51M).
Orchestra BioMed is unprofitable as of last fiscal year, with gross margin of 99%, EBITDA margin of (153%), and net margin of (157%).
Financial data powered by Morningstar, Inc.
Orchestra BioMed Stock Performance
Orchestra BioMed has current market cap of $243M, and enterprise value of $165M.
Market Cap Evolution
Orchestra BioMed's stock price is $4.06.
Orchestra BioMed share price increased by 1.8% in the last 30 days, and by 42.5% in the last year.
Orchestra BioMed has an EPS (earnings per share) of $-0.88.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $165M | $243M | 0.0% | 1.8% | -6.4% | 42.5% | $-0.88 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOrchestra BioMed Valuation Multiples
Orchestra BioMed trades at 8.1x EV/Revenue multiple, and (2.4x) EV/EBITDA.
EV / Revenue (LTM)
Orchestra BioMed Financial Valuation Multiples
As of May 26, 2026, Orchestra BioMed has market cap of $243M and EV of $165M.
Orchestra BioMed has a P/E ratio of (3.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Orchestra BioMed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Orchestra BioMed Margins & Growth Rates
Orchestra BioMed decreased revenue by 98% but EBITDA grew by 87% in the last fiscal year.
In the most recent fiscal year, Orchestra BioMed reported gross margin of 99%, EBITDA margin of (153%), and net margin of (157%).
Orchestra BioMed Margins
Orchestra BioMed Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Orchestra BioMed Operational KPIs
Orchestra BioMed's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $1.2M for the same period.
Orchestra BioMed's Rule of 40 is (17635%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Orchestra BioMed's Rule of X is (17783%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Orchestra BioMed Competitors
Orchestra BioMed competitors include Asterasys, Stratec, OraSure, Affluent Medical, Profound Medical, RxSight, Ascom, Humacyte, Eurobio Scientific and Onward Medical.
Most Orchestra BioMed public comparables operate across Medical Devices, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 9.0x | 7.6x | 27.2x | 22.0x | |||
| 1.3x | 1.2x | 9.4x | 9.0x | |||
| 0.7x | 0.7x | (2.0x) | (2.1x) | |||
| — | 393.2x | — | (12.1x) | |||
| 13.0x | 10.2x | (5.7x) | (6.3x) | |||
| 0.3x | 0.3x | (1.3x) | (0.9x) | |||
| 0.6x | 0.6x | 5.2x | 5.3x | |||
| 122.9x | 60.1x | (11.3x) | — | |||
This data is available for Pro users. Sign up to see all Orchestra BioMed competitors and their valuation data. Start Free Trial | ||||||
Orchestra BioMed Funding History
Before going public, Orchestra BioMed raised $243M in total equity funding, across 5 rounds.
Orchestra BioMed Funding Rounds
Orchestra BioMed Investment Activity
Orchestra BioMed has invested in 1 company to date.
Latest investment by Orchestra BioMed was on May 17th 2022. Orchestra BioMed invested in Vivasure Medical in their $23M Series D round (EV/Revenue multiple of ).
Latest Investments by Orchestra BioMed
| Description | Vivasure Medical is a Galway, Ireland-based developer of the PerQseal vascular closure device for large-bore arteriotomies. The company focuses on minimally invasive solutions for transcatheter aortic valve replacements and endovascular aneurysm repairs. Its collagen plug system achieves immediate hemostasis, reducing complications compared to manual compression. Vivasure Medical has completed European clinical trials and pursues U.S. FDA approval through partnerships with interventional cardiology centers. |
| HQ Country | |
| HQ City | Galway |
| Deal Date | 17 May 2022 |
| Round | Series D |
| Raised | $23M |
| Investors | Evonik Venture Capital; Fountain Healthcare Partners; LSP Health Economics Fund; Orchestra BioMed; Panakes Partners |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Orchestra BioMed investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Orchestra BioMed
| When was Orchestra BioMed founded? | Orchestra BioMed was founded in 2018. |
| Where is Orchestra BioMed headquartered? | Orchestra BioMed is headquartered in United States. |
| How many employees does Orchestra BioMed have? | As of today, Orchestra BioMed has over 70 employees. |
| Who is the CEO of Orchestra BioMed? | Orchestra BioMed's CEO is David P. Hochman. |
| Is Orchestra BioMed publicly listed? | Yes, Orchestra BioMed is a public company listed on Nasdaq. |
| What is the stock symbol of Orchestra BioMed? | Orchestra BioMed trades under OBIO ticker. |
| When did Orchestra BioMed go public? | Orchestra BioMed went public in 2023. |
| Who are competitors of Orchestra BioMed? | Orchestra BioMed main competitors include Asterasys, Stratec, OraSure, Affluent Medical, Profound Medical, RxSight, Ascom, Humacyte, Eurobio Scientific, Onward Medical. |
| What is the current market cap of Orchestra BioMed? | Orchestra BioMed's current market cap is $243M. |
| What is the current revenue of Orchestra BioMed? | Orchestra BioMed's last 12 months revenue is $20M. |
| What is the current revenue growth of Orchestra BioMed? | Orchestra BioMed revenue growth (NTM/LTM) is (97%). |
| What is the current EV/Revenue multiple of Orchestra BioMed? | Current revenue multiple of Orchestra BioMed is 8.1x. |
| Is Orchestra BioMed profitable? | No, Orchestra BioMed is not profitable. |
| What is the current EBITDA of Orchestra BioMed? | Orchestra BioMed has negative EBITDA and is not profitable. |
| What is Orchestra BioMed's EBITDA margin? | Orchestra BioMed's last 12 months EBITDA margin is (340%). |
| What is the current EV/EBITDA multiple of Orchestra BioMed? | Current EBITDA multiple of Orchestra BioMed is (2.4x). |
| What is the current FCF of Orchestra BioMed? | Orchestra BioMed's last 12 months FCF is ($57M). |
| What is Orchestra BioMed's FCF margin? | Orchestra BioMed's last 12 months FCF margin is (282%). |
| What is the current EV/FCF multiple of Orchestra BioMed? | Current FCF multiple of Orchestra BioMed is (2.9x). |
| How many companies Orchestra BioMed has acquired to date? | Orchestra BioMed hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Orchestra BioMed has invested to date? | As of May 2026, Orchestra BioMed has invested in 1 company. |
| What was the last Orchestra BioMed investment? | On 17th May 2022 Orchestra BioMed invested in Vivasure Medical, participating in a $23M Series D round, alongside Evonik Venture Capital, Fountain Healthcare Partners, LSP Health Economics Fund, and Panakes Partners. |
| In what companies Orchestra BioMed invested in? | Orchestra BioMed invested in Vivasure Medical. |
See public comps similar to Orchestra BioMed
Lists including Orchestra BioMed
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
